Quinoline derivatives as inhibitors of mek enzymes
CA 2370838 A1 · Owner: Astrazeneca Ab · Inventors: Gibson, Keith Hopkinson
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A compound of formula (I) or a pharmaceutically acceptable salt thereof; for use as a medicament wherein: n is 0-1; Y is selected from -NH- -O-, -S-, or -, NR7- where R7 is alkyl of 1-6 carbon atoms R5 is chloro or bromo; Y is selected from -NH-, -O-, -S-, or -NR7- where R7 is alkyl of 1-6 carbon atoms R6 is a specified cyclic group which may be substituted by various specified substituents, or R6 is a group -R8-X-R9. The compounds are particularly useful in the inhibition of MEK enzymes.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 3, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 3, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 3, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.